• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GALDERMA Q-MED AB RESTYLANE; IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GALDERMA Q-MED AB RESTYLANE; IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Lot Number 19548
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Abscess (1690); Cellulitis (1768); Skin Infection (4544); Skin Inflammation/ Irritation (4545); Swelling/ Edema (4577)
Event Date 12/06/2021
Event Type  Injury  
Manufacturer Narrative
Company comment: the serious events of cellulitis, abscess, inflammation, infection at implant site and the non-serious event of oedema at implant site were considered expected and possibly related to the treatments.Serious criteria include the need for surgical and multiple medical interventions and hospitalization to prevent permanent damage.Potential root cause include injection procedure associated with inadequate aseptic technique.Potential contributory factor or alternative root cause of the events include past treatment with pmma, as reactivation of pmma inflammation was indicated in the received case report.The case meets the criteria for expedited reporting to the regulatory authorities.Evaluation text: restylane kysse-routine investigations have been performed and provide sufficient information to assess the potential root cause and indicate a possible association to the treatment procedure.The reported lot number was valid and verified the reported product.No potential quality issues have been identified in the manufacturing process of the specified batch.The batch is manufactured and released according to symatese quality management system.The information in this case does not indicate a non-conforming product or malfunction.The performed investigations are therefore considered adequate and no additional investigations will be conducted.Restylane-routine investigations have been performed and provide sufficient information to assess the potential root cause and indicate a possible association to the treatment procedure.The reported lot number was valid and verified the reported product.No potential quality issues have been identified in the manufacturing process of the specified batch.The batch is manufactured and released according to galderma quality management system.The information in this case does not indicate a non-conforming product or malfunction.The performed investigations are therefore considered adequate and no additional investigations will be conducted.
 
Event Description
Case reference number (b)(4) is a spontaneous report sent on 13-dec-2021 by a physician, which refers to a (b)(6) caucasian male patient.No information about medical history, concomitant medication or history of allergies had been provided.The patient had previously received treatment with pmma [polymethylmethacrylate].Treatment date and location were not reported.On (b)(6) 2021, the patient received treatment with 1 ml of restylane kysse (lot s2202870006) to lips using cannula 25g and needle with retro-injection technique.On (b)(6) 2021, the patient received treatment with 2 ml restylane (lot 19548), 0.5 ml on each side of pyriform sinus and 0.5 ml in each side of dark circles, using cannula 25 g (in dark circles) and needle (in dark circles and pyriform sinus) with bolus technique in pyriform sinus and retro-injection technique in dark circles.On (b)(6) 2021, the patient experienced important ipsilateral edema (implant site oedema), reactivation of pmma [polymethylmethacrylate] inflammation (implant site inflammation) from past procedures and infection (implant site infection) at the right region of the nasolabial sulcus.On an unknown date in (b)(6) 2021, the patient also experienced cellulitis (implant site cellulitis) and abscess (implant site abscess).On (b)(6) 2021, the patient underwent following lab test: complete blood count (result: 15,890/mm) and sinus tomography which showed the presence of exogenic and asymmetric material at subcutaneous hemifaces and an acute inflammatory process could not be excluded.As a corrective treatment, the patient received the prescription of prednisolone and dipyrone and had difficulty to buy these medications (use of dypirone was not mentioned).In (b)(6) 2021, the patient had received additional corrective treatments with clavulin [amoxicillin sodium, clavulanate potassium], cefalexin [cefalexin], paco [codeine phosphate, paracetamol], nimesulide [nimesulide] and prednisolone [prednisolone].On (b)(6) 2021, a drainage was performed in a hospital environment besides treatment with medications.On (b)(6) 2021, the patient was hospitalized to perform a new tomography as the previous one had only shown signs of acute inflammation.However, the patient refused to provide the result of the second tomography to the reporter.At the time of report, the patient was still hospitalized.The events intensity was assessed as serious by reporter.The causal relationship between restylane kysse and restylane and all reported events was reported as possible.Outcome at the time of the report cellulitis was not recovered/not resolved/ongoing.Abscess was not recovered/not resolved/ongoing.Inflammation was not recovered/not resolved/ongoing.Infection was not recovered/not resolved/ongoing.Edema was not recovered/not resolved/ongoing.Tracking list: v.0 initial.V.1 fu received on (b)(6) 2021 from another physician: events (implant site inflammation and infection) added.Patient demographics, past filler treatment, suspect device implant date, location, volume, needle type, injection technique, hospitalization details, outcome, reporter causality, corrective treatments and laboratory test details were added.Brr results were received.
 
Event Description
Case reference number (b)(4) is a spontaneous report sent on (b)(6) 2021 by a physician, which refers to a 36-year-old caucasian male patient.No information about medical history or history of allergies had been provided.The patient had previously received treatment with pmma [polymethylmethacrylate] by another healthcare professional in (b)(6) 2021.The injection sites were the nasolabial area, chin, jaw and zygoma.On (b)(6) 2021, the patient received treatment with 1 ml of restylane kysse (lot s2202870006) to lips using cannula 25g and needle with retro-injection technique.The reporter confirmed that the patient did not experience any adverse events in lips.On (b)(6) 2021, the patient received treatment with 2 ml restylane (lot 19548), 0.5 ml on each side of pyriform sinus and 0.5 ml in each side of dark circles, using cannula 25 g (in dark circles) and needle (in dark circles and pyriform sinus) with bolus technique in pyriform sinus and retro-injection injection technique in dark circles.On (b)(6) 2021, the patient experienced important ipsilateral edema (implant site oedema), reactivation of pmma [polymethylmethacrylate] inflammation (implant site inflammation) from past procedures and infection (implant site infection) at the right region of the nasolabial sulcus.On an unknown date in (b)(6) 2021, the patient also experienced cellulitis (implant site cellulitis) and abscess (implant site abscess).On (b)(6) 2021, the patient underwent following lab test: complete blood count (result: 15,890/mm) and sinus tomography which showed the presence of exogenic and asymmetric material at subcutaneous hemifaces and an acute inflammatory process could not be excluded.As a corrective treatment, the patient received the prescription of prednisolone and dipyrone and had difficulty to buy these medications (use of dypirone was not mentioned).In (b)(6) 2021, the patient had received additional corrective treatments with clavulin [amoxicillin sodium, clavulanate potassium], cefalexin [cefalexin], paco [codeine phosphate, paracetamol], nimesulide [nimesulide] and prednisolone [prednisolone].On (b)(6) 2021, a drainage was performed in a hospital environment besides treatment with medications.On (b)(6) 2021, the patient was hospitalized to perform a new tomography as the previous one had only shown signs of acute inflammation.However, the patient refused to provide the result of the second tomography to the reporter.At the time of report, the patient was still hospitalized.The events intensity was assessed as serious by reporter.The causal relationship between restylane and all reported events was reported as possible.Outcome at the time of the report: cellulitis was not recovered/not resolved/ongoing.Abscess was not recovered/not resolved/ongoing.Inflammation was not recovered/not resolved/ongoing.Infection was not recovered/not resolved/ongoing.Edema was not recovered/not resolved/ongoing.Tracking list: v.0 initial; v.1 fu received on 15-dec-2021 from another physician: events (implant site inflammation and infection) added.Patient demographics, past filler treatment, suspect device implant date, location, volume, needle type, injection technique, hospitalization details, outcome, reporter causality, corrective treatments and laboratory test details were added.Brr results were received.V.2 fu received on 28-dec-2021 from the same physician who forwarded the first follow-up (secondary reporter).Past filler implant date and locations were updated.The reporter confirmed that the patient did not experience any adverse events in lips.Hence restylane kysse assessed as concomitant treatment.
 
Manufacturer Narrative
Company comment: the serious events of cellulitis, abscess, inflammation, infection at implant site and the non-serious event of oedema at implant site were considered expected and possibly related to the restylane treatment.Serious criteria include the need for surgical and multiple medical interventions and hospitalization to prevent permanent damage.Potential root cause include injection procedure associated with inadequate aseptic technique.Potential contributory factor or alternative root cause of the events include past treatment with pmma, as reactivation of pmma inflammation was indicated in the received case report.The case meets the criteria for expedited reporting to the regulatory authorities.Evaluation text: restylane kysse-routine investigations have been performed and provide sufficient information to assess the potential root cause and indicate a possible association to the treatment procedure.The reported lot number was valid and verified the reported product.No potential quality issues have been identified in the manufacturing process of the specified batch.The batch is manufactured and released according to symatese quality management system.The information in this case does not indicate a non-conforming product or malfunction.The performed investigations are therefore considered adequate and no additional investigations will be conducted.Restylane-routine investigations have been performed and provide sufficient information to assess the potential root cause and indicate a possible association to the treatment procedure.The reported lot number was valid and verified the reported product.No potential quality issues have been identified in the manufacturing process of the specified batch.The batch is manufactured and released according to galderma quality management system.The information in this case does not indicate a non-conforming product or malfunction.The performed investigations are therefore considered adequate and no additional investigations will be conducted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESTYLANE
Type of Device
IMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
GALDERMA Q-MED AB
seminariegatan 21
uppsala, SE-75 228
SW  SE-75228
Manufacturer (Section G)
GALDERMA Q-MED AB
seminariegatan 21
uppsala, SE-75 228
SW   SE-75228
Manufacturer Contact
randy russell
14501 n. freeway
fort worth, TX 76177
MDR Report Key13078434
MDR Text Key288287929
Report Number9710154-2021-00080
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Reporter Country CodeBR
PMA/PMN Number
P040024
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 01/14/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date04/30/2024
Device Lot Number19548
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 12/13/2021
Initial Date FDA Received12/23/2021
Supplement Dates Manufacturer Received12/28/2021
Supplement Dates FDA Received01/14/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured05/20/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age36 YR
Patient SexMale
-
-